Search results
Results from the WOW.Com Content Network
Singletary stayed at MD Anderson as a faculty member, later serving as chief of the melanoma surgery and breast surgery sections. Her interest in breast cancer was influenced by MD Anderson radiation oncologist Eleanor Montague. [2] In 1992, the President's Cancer Panel appointed her to a special committee that examined the state of breast ...
The MD Anderson Cancer Center's Africa Initiative, part of its Global Oncology Program launched in September 2022, aims to reduce the cancer burden in low- and middle-income countries (LMICs) through comprehensive education, training, and collaborative research. One of the flagship projects under this initiative is Project ECHO (Extension for ...
Gibbs was selected to be an NCI-funded clinical oncology programs in 1983 and has been continuously funded by NCI for thirty years. Gibbs Cancer Center became an exclusive host affiliate of the MD Anderson Cancer Center in 2005 and established the Bearden-Josey Center for Breast Health in 2008.
Triple-positive breast cancers are among the more aggressive forms of the disease, but they’re also the most treatable variety, according to MD Anderson Cancer Center. When a tumor is “triple ...
Alicia Fivecoat, who was recently diagnosed with breast cancer, was getting bloodwork done at MD Anderson Cancer Center in Houston in January, when her young granddaughter Whitney was diagnosed ...
A Black mom, 33, found a gumball sized lump in her breast. She had stage 3 triple negative cancer. A clinical trial saved her life. Now she educates other Black women.
Virgil Craig Jordan, CMG, OBE, FMedSci, (July 25, 1947 – June 9, 2024) was an American and British scientist specializing in drugs for breast cancer treatment and prevention. [1] He was Professor of Breast Medical Oncology, and Professor of Molecular and Cellular Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas.
MDA-MB-231 (M D Anderson - Metastatic Breast - 231) is a human breast cancer cell line isolated at M D Anderson in 1973 that is used in therapeutic research, especially in the context of triple negative breast cancer. [1] [2]